Source link : https://newshealth.biz/health-news/rigosertib-shows-promise-in-eb-associated-skin-cancer/
TOPLINE: Rigosertib, a polo-like kinase 1 (PLK1) inhibitor, demonstrated antitumor efficacy in patients with recessive dystrophic epidermolysis bullosa (RDEB) and advanced squamous cell carcinoma (SCC), with an objective response achieved in four of five patients. METHODOLOGY: Researchers conducted an open-label, single-arm phase 2 study in Austria and the United States of five patients with advanced, […]
The post Rigosertib Shows Promise in EB-Associated Skin Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-03 07:32:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8